The efficacy and safety of adding the probiotic Saccharomyces boulardii to standard triple therapy for eradication of Helicobacter pylori; a randomized controlled trial
Gastroenterology and Hepatology from Bed to Bench,
Vol. 6 (2013),
Page Gastroenterol Hepatol Bed Bench 2013;6(Suppl.1):S99-S104
Purpose: Evaluating the efficacy and safety of adding the probiotic Saccharomyces boulardiito standard triple therapy for eradication of Helicobacter pylori.
Methods and materials: In this randomized controlled trial we evaluated 160 adult patients with biopsy confirmed H.Pylori infection referred to gastroenterology ward of Taleghani hospital. The patients were randomized into two treatment regimens: patients in group A (n=80) were given amoxicillin (1000 mg, b.i.d), clarithromycin (500 mg, b.i.d), omeprazole (20 mg, b.i.d) and probiotic of saccaromyces boularidi (Yomogi) (250 mg, b.i.d) for 14 days, moreover patients in group B (n=80) were given amoxicillin (1000 mg, b.i.d), clarithromycin (500 mg b.i.d) and omeprazole (20 mg,b.i.d) for 14 days.
Results: 160 patients (66 male 41.25%, 94female 58.75%) with the mean age of 47.1±11.4 years were evaluated. The success rate for H. pylori eradication in group A was higher 75(87.5%) than group B 65 (81.2%), but the difference between two groups was not significant (p=0.350). Moreover, in case group side effects as nausea, diarrhea, abdominal discomfort and bloating were significantly lower than control group in first and second weeks.
Conclusion: The result of this study showed that saccaromyces boularidi decreased the adverse effects associated with H.pylori therapy but did not significantly decrease the eradication rate of H.pylori.
How to Cite
- Abstract Viewed: 122 times
- PDF Downloaded: 354 times